Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Inventory (2016 - 2026)

Myriad Genetics has reported Inventory over the past 15 years, most recently at $30.6 million for Q4 2025.

  • Quarterly Inventory rose 11.27% to $30.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $30.6 million through Dec 2025, up 11.27% year-over-year, with the annual reading at $30.6 million for FY2025, 11.27% up from the prior year.
  • Inventory was $30.6 million for Q4 2025 at Myriad Genetics, down from $31.6 million in the prior quarter.
  • Over five years, Inventory peaked at $31.6 million in Q3 2025 and troughed at $15.3 million in Q4 2021.
  • The 5-year median for Inventory is $23.6 million (2021), against an average of $23.1 million.
  • Year-over-year, Inventory tumbled 43.54% in 2021 and then soared 46.1% in 2023.
  • A 5-year view of Inventory shows it stood at $15.3 million in 2021, then surged by 31.37% to $20.1 million in 2022, then increased by 9.45% to $22.0 million in 2023, then increased by 25.0% to $27.5 million in 2024, then increased by 11.27% to $30.6 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Inventory are $30.6 million (Q4 2025), $31.6 million (Q3 2025), and $28.7 million (Q2 2025).